Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III
Age and Ageing · 31.05.2025 · 54 (6)
DOI: 10.1093/ageing/afaf139 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Age and Ageing, online erschienen am 04.06.2025. Verfasst von Hongyu Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverp…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Stroke, Thromboembolism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Older age increases the risk of thromboembolism (TE) and major bleeding in atrial fibrillation (AF) patients, but limited evidence exists regarding the older population (age ≥ 80) especially from different global regions. Data on benefits of oral anticoagulants in these very old individuals are also limited.
Methods
From the prospective, multicenter Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation registry, we analysed by age all-cause death, cardiovascular death, major adverse cardiovascular events (MACE), TE, major bleeding, stroke, and myocardial infarction (MI) over 3-years follow-up.
Results
Of 7652 patients aged ≥75 years (age 80.1 ± 3.9 years, 47.1% male), 4006 were ≥ 80 years (age 83.4 ± 3.9 years, 43.5% male). After multivariable adjustment, older patients had a higher risk of all-cause death (HR:1.94, 95% CI: 1.67–2.27), cardiovascular death (HR: 2.17, 95% CI: 1.71–2.74), MACE (HR: 1.57, 95% CI: 1.32–1.86), TE (HR: 1.45, 95% CI: 1.14–1.83), major bleeding (HR: 1.30, 95% CI: 1.04–1.63), stroke (HR: 1.38, 95% CI: 1.06–1.80) and MI (HR: 1.59, 95% CI:1.14–2.22). Compared with VKA, NOAC use in patients ≥80 years was associated with lower risks of all-cause death (HR: 0.79, 95% CI: 0.65–0.97), cardiovascular death (HR: 0.70, 95% CI: 0.51–0.96), MACE (HR: 0.72, 95% CI: 0.56–0.92), and major bleeding (HR: 0.66, 95% CI: 0.48–0.92). NOACs were more beneficial than warfarin for mortality, MACE and major bleeding in frail patients. The risk of clinical events associated with older patients was primarily seen in Europe and Asia (p-interaction > 0.05), but the effectiveness and safety of NOACs vs. warfarin was consistent across regions.
Conclusions
Older age was independently associated with higher risk of death, major bleeding, TE and MACE. Compared with VKA, NOACs show improved effectiveness and safety in the older and patients with frailty, with similar efficacy across regions and ethnic groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool L7 8TX, UK.
- Department of Genetic Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.1, MINDE ROAD, Nanchang, Jiangxi 330006, China.
- Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Translational and Precision Medicine, University of Rome La Sapienza, Rome, Lazio, Italy.
- Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Jiangxi Provincial Key Laboratory of Molecular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University. Nanchang, Jiangxi, China.
ORCID-Profile: Hongyu Liu, Yang Chen, Giulio Francesco Romiti, Gregory Y H Lip
Zitieren
APA
Liu, H., Chen, Y., Huang, B., Lam, S. H. M., Romiti, G. F., Liu, Y., Olshansky, B., Huisman, M., Hong, K., Chao, T. F., & Lip, G. Y. H. (2025). Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III. Age and Ageing, 54(6). https://doi.org/10.1093/ageing/afaf139
Vancouver
Liu H, Chen Y, Huang B, Lam SHM, Romiti GF, Liu Y, et al. Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III. Age and Ageing. 2025;54(6). doi:10.1093/ageing/afaf139
BibTeX
@article{Liu2025,
author = {Liu, Hongyu and Chen, Yang and Huang, Bi and Lam, Steven Ho Man and Romiti, Giulio Francesco and Liu, Yang and Olshansky, Brian and Huisman, Menno and Hong, Kui and Chao, Tze-Fan and Lip, Gregory Y H},
title = {Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III},
journal = {Age and Ageing},
year = {2025},
volume = {54},
number = {6},
doi = {10.1093/ageing/afaf139}
}
EUVIMED